Business Wire

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...
Time

Why Johnson & Johnson's CEO Welcomes Scrutiny

Javed is a senior editor at TIME, based in the London bureau. Joaquin Duato, chairman and CEO of Johnson & Johnson Javed is a senior editor at TIME, based in the London bureau. It’s nearly a year and ...
Seeking Alpha

Eli Lilly, J&J working with Nvidia to boost AI capabilities

Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia (NVDA) technology to either enhance their products or assist in the development of new treatments, the chipmaker's CEO said ...
Business Wire

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the ...
The Motley Fool

Better Buy Right Now: Johnson & Johnson Vs. Pfizer

Johnson & Johnson is one of the largest pharmaceutical stocks by market cap. Pfizer's dividend offers a hefty yield. Revenue is growing for J&J, while Pfizer is leaning on acquisitions to help spur ...